Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$25.18 USD

25.18
1,252,759

+1.41 (5.93%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $25.20 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Why Is Pacira (PCRX) Up 14.6% Since Last Earnings Report?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?

PCRX vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

Zacks Equity Research

Pacira (PCRX) Q1 Earnings and Revenues Top Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

PCRX or CTLT: Which Is the Better Value Stock Right Now?

PCRX vs. CTLT: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock

Pacira BioSciences (PCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why

Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra

The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra

Zacks Equity Research

PCRX or ZTS: Which Is the Better Value Stock Right Now?

PCRX vs. ZTS: Which Stock Is the Better Value Option?

Tirthankar Chakraborty headshot

5 Best Stocks to Buy in a Coronavirus-Led Bear Market

The period of a typical bear market has a propensity to be pretty lengthy. On average, bear market for the Dow and the S&P 500 lasts 206 and 146 trading days, respectively.

Zacks Equity Research

Why Pacira (PCRX) Could Be an Impressive Growth Stock

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Pacira (PCRX)

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group

The Zacks Analyst Blog Highlights: Pacira Pharmaceuticals, Computer Programs and Systems, Mattel and Performance Food Group

Supriyo Bose headshot

Coronavirus Triggers Rate Cut: Stocks That Can Defy Market Fall

Amid the doom and gloom, we have cherry picked four stocks that possess potential to perform well in the long run.

Zacks Equity Research

Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q4 Loss

Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.

Zacks Equity Research

3 Reasons Why Pacira (PCRX) Is a Great Growth Stock

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

PCRX vs. ZTS: Which Stock Is the Better Value Option?

PCRX vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line

Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for February 21st

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st

Zacks Equity Research

Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss

Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.

Sanghamitra Saha headshot

3 Top-Ranked Stocks Poised for an Earnings Beat

Count on these top-ranked stocks that are likely to beat earnings estimates in their next releases.

    Zacks Equity Research

    Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4

    Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.

    Zacks Equity Research

    FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA

    The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.

    Zacks Equity Research

    Will Pacira BioSciences Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Pacira BioSciences.